The global fibromyalgia treatment market is projected to expand from USD 2.77 billion in 2023 to approximately USD 4.13 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2032.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5139
Fibromyalgia affects around 4 million adults in the United States, roughly 2% of the adult population. While the exact cause remains unknown, effective treatment options are available. As the need for these treatments grows, researchers are exploring new approaches beyond traditional medications.
Fibromyalgia is characterized by widespread muscle pain, fatigue, difficulty concentrating, and other emotional and physical symptoms. Although people with fibromyalgia experience pain in muscles and soft tissues, there is no visible inflammation in these areas.
Research suggests that fibromyalgia may be linked to how the body processes pain, a condition known as central sensitization syndrome. It is more common in women, with approximately 6.4% of the U.S. population affected (7.7% in women and 4.9% in men). Studies in Europe and South America show similar rates, ranging from 3.3% to 8.3%. Fibromyalgia is more prevalent as people age, often affecting women between the ages of 20 and 55. Teenagers can also experience fibromyalgia at similar rates as adults, and in specialized pain clinics, over 40% of patients meet the criteria for the condition.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/fibromyalgia-treatment-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5139
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More